. Si-clairance-de-la-créatinine, 60 ml/min : 900 mg 1 fois/jour en traitement d'entretien ou prophylaxie Si clairance de la créatinine entre 40-59 ml/min : 450 mg 2 fois/jour en traitement d'attaque

. Si-clairance-de-la-créatinine-entre, 40-59 ml/min : 450 mg 1 fois/jour en traitement d'entretien ou prophylaxie Si clairance de la créatinine entre 25-39 ml/min: 450 mg 1 fois/jour en traitement d'attaque

E. P. Acosta, et al ? Ganciclovir population pharmacokinetics in neonatesfollowing intravenous administration of ganciclovir and oral administration of a liquid valganciclovir formulation

M. Adachi, et al ? Expression of MRP4 confers resistance to ganciclovir and compromises bystander cell killing

R. Agbaria, Biosynthetic Ganciclovir Triphosphate: Its Isolation and Characterization from Ganciclovir-Treated Herpes Simplex Thymidine Kinase-Transduced Murine Cells, Biochemical and Biophysical Research Communications, vol.289, issue.2
DOI : 10.1006/bbrc.2001.6011

M. K. Al-banna, et al -Experimental design and efficient parameter estimation in population pharmacokinetics

J. Alcorn, Acyclovir, Ganciclovir, and Zidovudine Transfer into Rat Milk, Antimicrobial Agents and Chemotherapy, vol.46, issue.6
DOI : 10.1128/AAC.46.6.1831-1836.2002

P. Aman, Et al -Epstein-Barr virus susceptibility of normal human B lymphocyte populations

K. Atkinson, Prophylactic ganciclovir is more effective in HLA-Identical family member marrow transplant recipients than in more heavily immune-suppressed HLA-identical urelated donor marrow transplant recipients, p.295

G. Avetisyan, et al ? Impact on the cytomegalovirus (CMV) viral load by CMV-specific T-cell immunity in recipients of allogeneic stem cell transplantation

M. L. Avila-aguëro, et al ? Ganciclovir therapy in cytomegamovirus (CMV) infection in immunocompetent pedaiatric patients

E. Ayala, Valganciclovir is safe and effective as pre-emptive therapy for CMV infection in allogeneic hematopoietic stem cell transplantation, Bone Marrow Transplantation, vol.99, issue.9
DOI : 10.1182/blood.V99.4.1159

F. Baldanti, et al ? Monitoring human cytomegalovirus infection in transplant recipients

J. Balzarini, et al ? 2', 3'-dideoxycytidine: Regulation of its metabolism and antiretroviral potency by natural pyrimidine nucleosides and by inhibitors of pyrimidine nucleotide synthesis

J. Balzarini, et al ? Superior cytostatic activity of the ganciclovir elaidic acid ester due to the prolonged intracellular retention of ganciclovir anabolites in herpes simplex virus type 1

M. Battiwalla, et al -Ganciclovir inhibits lymphocyte proliferation by impairing DNA synthesis

F. Becher, Improved method for the simultaneous determination of d4T, 3TC, and ddI intracellular phosphorylated ababolites in human peripheral blood mononuclear cells using high performance liquid chromatography/tandem mass spectrometry

F. Becher, et al ? Development of a direct assay for measuring intracellular AZT triphosphate in humans peripheral blood mononuclear cells

F. Becher, et al ? A strategy for liquid chromatography/tandem mass spectrometric assays of intracellular drugs: application to the validation of the triphosphrylated anabolite of antiretrovirals in peripheral blood mononuclear cells

C. Beltinger, et al ? Herpes Simplex virus thymidine kinase/ganciclovir induced apoptosis involves ligand-independent death receptor aggregation and activation of capasases

M. Benyesh-melnick, Studies on human leukemia. I. Spontaneous lymphoblastoid transformation of fibroblastic bone marrow cultures derived from leukemic and non-leukemic children, J Natl Cancer Inst, issue.31, p.1311, 1963.

K. K. Biron, et al ? Metabolic activation of the nucleoside analog 9-(2-hydroxy-1- (hydroxymethyl) ethoxymethyl)guanine in human diploid fibroblasts infected with human cytomegaloviruses, Proc Natl Acad Sci, issue.82, pp.2473-2480, 1985.

K. K. Biron, et al ? A human cytomegalovirus mutant resistant to the nucleoside analog 9-(2- hydroxy-1-(hydroxymethyl) ethoxymethyl)guanine (BW B759U) induces reduced levels of BW B759U triphosphate, Proc Natl Acad Sci, issue.83, pp.8769-73, 1986.

N. Bleyzac, et al ? High performance liquid chromatographic determination of ganciclovir nucleotides in human myocardial tissue

M. Boeckh, et al ? Late cytomegalovirus disease and mortality in recipients of allogeneic hematopoietic stem cell transplants: importance of viral load and T -cell immnunity

G. Boivin, Absence of Cytomegalovirus???Resistance Mutations after Valganciclovir Prophylaxis, in a Prospective Multicenter Study of Solid???Organ Transplant Recipients, The Journal of Infectious Diseases, vol.189, issue.9, pp.1615-1633, 2004.
DOI : 10.1086/382753

G. Boivin, et al ? Early effects of ganciclovir therapy on the quantity of cytomegalovirus DNA in leukocytes of immunocompromised patients, Antimicrob Agents Chemother, issue.41, pp.860-862, 1997.

S. B. Boppana, et al -Symptomatic congenital cytomegalovirus infection: neonatal morbidity and mortality

R. Boulieu, et al -High-performance liquid chromatographic determination of ganciclovir in plasma

S. D. Brown, et al ? Hydrophilic interaction liquid chromatography/electrospray masss spectrometry determination of acyclovir in pregnant rat plasma and tissues, Rapid Commun Mass Spectrom, issue.16, pp.1871-1877, 2002.

A. Busca, et al ? Oral valganciclovir as preemptive therapy for cytomegalovirus infection post allogeneic stem cell transplantation, Transpl Infect Dis, issue.9, pp.102-109, 2007.

M. A. Campanero, et al ? Development and validation of a sensitive method for the determination of ganciclovir in humazn plasma samples by reversed-phase highperformance liquid chromatography, J Chromatogr B, issue.706, pp.311-318, 1998.

E. Castognola, et al ? Cytomegalovirus infection after bone marrow transplantation in children

Y. Cheng, et al ? Metabolism of 9-(1-3-dihydroxy-2-propoxymethyl)guanine, a new antiherpes virus compound

Y. C. Cheng, et al -Unique spectrum of activity of 9-[(1,3-dihydroxy-2-propoxy)methyllguanine against herpesviruses in vitro and its mode of action against herpes simplex virus type 1

Y. Cheng, -propoxymethyl)guanine, a new antiherpesvirus compound, on synthesis of macromolecules in herpes simplex virus-infected cells, pp.9-10

H. S. Cho, et al ? Bystander mediated regression of murine neuroblastoma via retroviral transfer of the HSV-TK gene

C. Jordan and M. , et al ? Spontaneous activation of latent cytomegalovirus from murine spleen explants ? Role of lymphocytes and macrophages in release and replication of virus

P. Collins, Comparison of the in vitro and in vivo antiherpes virus activities of the acyclic nucleosides, acyclovir and 9-(2-hydroxy-1-(hydroxymethyl) ethoxymethyl)guanine (BW B759U)

S. Compain, et al ? Improved method to quantify intracellular zidovudine mono and triphosphate in peripheral blood mononuclear cells by liquid chromatography ?tandem mass spectrometry

K. B. Crapnell, et al ? Human haematopoietic stem cells that mediate long-term in vivo enraftment are not susceptible to infection by human cytomegalovirus, p.299

J. Czarnecka, et al ? Application of solid phase extraction and high-performance liquid chromatography to qualitative and quantitative analysis of nucleotides and nucleosides in human cerebrospinal fluid

R. L. Davidson, et al -Inhibition of herpes simplex virus transformed and nontransformed cells by acycloguanosine: mechanisms of uptake and toxicity

L. De-bolle, et al ? Role of the human herpesvirus 6 U69-encoded kinase in the phosphorylation of ganciclovir

B. A. Domin, et al ? Membrane permeation mechanisms of 2', 3'-dideoxynucleosides, Biochem Pharmacol, issue.46, pp.725-734, 1993.

R. E. Dornsife, et al -In vitro potency of inhibition by antiviral drugs of hematopoietic progenitor colony formation correlates with exposure at hemotoxic levels in human immunodeficiency virus-positive humans

A. E. Duke, et al ? In vitro and in vivo activities of phosphate derivatives of 9-(1,3-hydroxy-2- propoxymethyl)-guanine against cytomegaloviruses

H. Einsele, et al -Risk factors for treatment failures in patients receiving PCR-based preemptive therapy for CMV-infection

H. Einsele, et al -Polymerase chain reaction monitoring reduces the incidence of cytomegalovirus disease and the duration and side effects of antiviral therapy after bone marrow transplantation

S. Eksborg, -The pharmacokinetics of antiviral therapy in paediatric patients

V. C. Emery, et al -The dynamics of human cytomegalovirus replication in vivo

M. A. Epstein, Virus particles in cultured lymphoblasts fromBrkitt's Lymphoma, Lancet, vol.1964, issue.1, pp.702-705

W. H. Feng, et al ? Chemotherapy induces lytic EBV replication and confezrs ganciclovir susceptibility tu EBV-positive epithelial cell tumors

W. H. Feng, et al ? Lytic induction therapy for Epstein-Barr virus-positive B-cell lymphomas

G. Filler, Prophylactic oral ganciclovir after renal transplantation-dosing and pharmacokinetics, Pediatric Nephrology, vol.12, issue.1
DOI : 10.1007/s004670050391

J. A. Fishman, et al ? Cytomegalovirus in transplantation ? challenging the status quo

J. A. Fishman, Infection in Solid-Organ Transplant Recipients, New England Journal of Medicine, vol.357, issue.25, pp.2601-2615, 2007.
DOI : 10.1056/NEJMra064928

S. J. Forman, et al -Treatment and prevention of cytomegalovirus pneumonia after bone marrow transplantation: where do we stand? Blood, pp.2392-2400, 1994.

K. B. Franck, et al ? Interaction of Herpes virus-induced DNA polymerase with 9-(1,3- dihydroxy-2-propoxymethyl)guanine triphosphate

V. R. Freitas, Activity of 9-(1,3-hydroxy-2-propoxymethyl)-guanine compared with that of acyclovir against human, monkey, and rodent cytomegaloviruses

L. M. Frenkel, et al ? Oral ganciclovir in children: pharmacokinetics, safety, tolerance and antiviral effects

E. N. Fung, et al ? Simultaneous determination of Ziagen a,d its phosphorylated metabolites by ion-pairing high performance liquid chromatography-tandem mass spectrometry

P. A. Furman, et al ? Metabolism of acyclovir in virus-infected and non infected cells

L. Galli, et al ? Valganciclovir for congenital CMV infection: a pilot study on plasma concentration in newborns and infants

J. Germershausen, A comparison of the antiviral agents 2???-nor-2???-deoxyguanosine and acyclovir: Uptake and phosphorylation in tissue culture and kinetics of in vitro inhibition of viral and cellular DNA polymerases by their respective triphosphates, Biochemical and Biophysical Research Communications, vol.116, issue.2
DOI : 10.1016/0006-291X(83)90530-2

B. G. Gentry, et al ? GCV phosphates are transferred between HeLa cells despite lack of bystander cytotoxicity

G. Gerna, Pathogenesis of human cytomegalovirus infection and cellular targets, Human Immunology, vol.65, issue.5
DOI : 10.1016/j.humimm.2004.02.009

K. Ghosh, Ultrastructural changes in peripheral blood neutrophils in a patient receiving ganciclovir for CMV pneumonitis following allogenic bone marrow transplantation, Bone Marrow Transplantation, vol.24, issue.4
DOI : 10.1038/sj.bmt.1701900

S. Giebel, The immunosuppressive effect of human cytomegalovirus infection in recipients of allogeneic hematopoietic stem cell transplantation, Bone Marrow Transplantation, vol.29, issue.6
DOI : 10.1038/sj.bmt.1703332

J. M. Goodrich, et al ? Early treatment with ganciclovir to preventy cytomegalovirus disease after allogeneic bone marrow transplantation

J. M. Goodrich, et al ? Strategies for the prevention of cytomegalovirus disease after marrow transplantation

S. Gouarin, et al -Congenital HCMV infection: a collaborative and comparative study of virus detection in amniotic fluid by culture and by PCR

J. Gordon, Et al -Soluble factor requirements for the autostimulatory growth of B lymphoblasts immortalized by Epstein-Barr virus

L. Grangeot-keros, et al -Should we routinely screen for cytomegalovirus antibody during pregnancy? Intervirology, pp.158-62, 1998.

B. Gratacap-cavallier, et al -Cytomegalovirus seroprevalence in French pregnant women: parity and place of birth as major predictive factors

R. Lorenzetti, et al ? Simultaneous quantification of GMP, AMP, cyclic GMP and cyclic AMP by liquid chromatography coupled to tandem mass spectrometry

J. P. Maciejewski, et al ? Infection of hematopoietic progenitor cells by human cytomegalovirus, Blood, issue.80, pp.170-178, 1992.

W. B. Mahony, Ganciclovir permeation of the human erythrocyte membrane, Biochemical Pharmacology, vol.41, issue.2
DOI : 10.1016/0006-2952(91)90485-N

W. B. Mahony, et al ? Membrane permeation characteristics of abacavir in human erythrocytes and human T-lymphoblastoid CD4+ CEM cells: comparison with carbovir

S. Majumdar, Mechanism of ganciclovir uptake by rabbit retina and human retinal pigmented epithelium cell line ARPE-19, Current Eye Research, vol.17, issue.2
DOI : 10.1080/09687680050117101

H. Maltazou, et al -Cytomegalovirus in adult marrow transplant recipients receiving ganciclovir prophylaxis: a retrospective study

J. F. Manischewitz, et al -Synergistic effect of ganciclovir and foscarnet on cytomegalovirus replication in vitro

D. J. Marmer, et al ? Comparison of flow cytometric analysis and [H] thymidine incorporation for measurements of the effects of drug toxicity on lymphocyte stimulation

S. Saigal, The outcome in children with congenital cytomegalovirus infection. A longitudinal follow-up study

B. Salzberger, et al -Neutropenia in allogeneic marrow transplant recipients receiving ganciclovir for prevention of cytomegalovirus disease : Risk factors and outcome

G. M. Schmidt, et al ? A randomized, controlled trial of prophylactic ganciclovir for cytomegalovirus pulmonary infection in recipients of allogeneic bone marrow transplants

J. C. Scott, et al -Ganciclovir in solid organ transplant recipients

D. S. Shewach, et al ? Metabolism of 2', 2'-difluoro-2'-deoxycytidine and radiation sensitization of human colon carcinoma cells

J. ?. Sinclair, Human cytomegalovirus: Latency and reactivation in the myeloid lineage, Journal of Clinical Virology, vol.41, issue.3
DOI : 10.1016/j.jcv.2007.11.014

H. Sindre, et al ? Human cytomegalovirus induced inhibition of hematopoietic cell line growth is initiated by events taking place before translation of viral gene products

N. ?. Singh, Antiviral drugs for cytomegalovirus in transplant recipients: advantages of preemptive therapy, Reviews in Medical Virology, vol.10, issue.5
DOI : 10.1093/clinids/22.3.537

J. T. Slusher, et al ? Intracellular zidovudine (AZT) and ZDV phosphates ad measured by a validated combined high pressure liquid chromatography-radioimmunoassay procedure

D. F. Smee, et al -Intracellular metabolism and enzymatic phosphorylation of 9-(1-3- dihydroxy-2-propoxymethyl)guanine and acyclovir in herpes simplex virus ?infected and uninfected cells

T. F. Smith, et al ? Quantitative real-time polymerase chain reaction for evaluating DNAemia due to Cytomegalovirus, Epstein-Barr virus and K virus in solid organ transplant recipients

R. Snoek, Inhibitory effects of potent inhibitors of human immunodeficiency virus and cytomegalovirus on the growth of human granulocyte-macrophage progenitor cells in vitro, European Journal of Clinical Microbiology & Infectious Diseases, vol.17, issue.Supplement 3
DOI : 10.1128/AAC.21.1.146

C. Solas, Intracellular nucleotides of (-) ? 2',3'-deoxy-3'-thiacytidine in peripheral blood mononuclear cells of a patient infected with human immunodeficiency virus

J. P. Sommadossi, et al -Toxicity of 3'-azido-3'-deoxythymidine and 9?(1,3-dihydroxy-2- propoxymethyl)guanine for normal human hematopoietic progenitor cells in vitro

S. Clair and M. H. , et al ? Inhibition of cellular ? and virally induced deoxyribonucleic acid polymerases by the triphosphate of acyclovir

S. Clair and M. H. , et al ? Inhibition by ganciclovir of cell growth and DNA synthesis of cells biochemically transformed with Herpesvirus genetic information

S. Clair and R. L. , Positive ion electrospray ionization tandem mass spectrometry coupled to ion-pairing high-performance liquid chromatography with a phosphate buffer for the quantitative analysis of intracellular nucleotides, Rapid Communications in Mass Spectrometry, vol.63, issue.17
DOI : 10.1021/ac00022a020

M. Tsuchie, et al ? Determination of anti-virus drug, ganciclovir, in human serum by HPLC with precolumn fluorescence derivatization using phenylglyoxal

W. E. Tucker, et al -Preclinical toxicology profile of acyclovir: An overview

J. E. Vela, et al ? Simultaneous quantification of the nucleotide analog adefovir, its phosphorylated anabolites and 2'-deoxyadenosine triphosphate by ion-pairing LC

J. Vethamuthu, et al ? Unexpectedly high inter and intrapatient variability of ganciclovir levels in children

R. Vij, et al ? Low-dose short-course intravenous ganciclovir as pre-emptive therapy for CMV viremia post allo-PBSC transplantation

M. Mem-eagle, Modifié) avec sels de Earle, avec glutamine, sans bicarbonate de sodium poudre Pour 100 ml de milieu final: MEM : 0,97 g Eau PPI : 100 ml Après dissolution et filtration (0,22 µ) ajouter : Bicarbonate de sodium (7,5%) : 1,66 ml Sérum de veau foetal (lot en cours) : 1 ml Pénicilline streptomycine 120 UI/ml, FORMULE M, vol.7120

J. Tocci, Après adsorption du virus, les cellules sont lavées trois fois et remises en suspension dans du RPMI 1640, à une concentration de environ 10 6 cellules/ml, Les cellules sont infectées pendant 2 heures à 37°C avec agitation fréquente, 1979.

. En, +. Le-poolcmv, C. +. Gcv0, C. Gcv1, C. et al., répartition dans 6 flacons de 50 ml à 10 6 cellules /ml

. Si, ml : prélever 5 µl de solA Si volume de 10 ml : prélever 10 µl de solA Si volume de 15 ml : prélever 15 µl de solA Si volume de 20 ml : prélever 20 µl de solA Si volume de 25 ml : prélever 25 µl de solA Si volume de 30 ml : prélever 30 µl de solA Si volume de 35 ml : prélever 35 µl de solA Si volume de 40 ml : prélever 40 µl de solA Si volume de 45 ml : prélever 45

H. Savolainen, I. Lautenschlager, H. Piiparinen, U. Saarinen-pihkala, L. Hovi et al., Human herpesvirus-6 and -7 in pediatric stem cell transplantation, Pediatric Blood & Cancer, vol.335, issue.6, pp.820-825, 2005.
DOI : 10.1093/infdis/167.3.735

M. Boeckh, V. Erard, D. Zerr, and J. Englung, Emerging viral infections after hematopoietic cell transplantation, Pediatric Transplantation, vol.28, issue.Suppl., pp.48-54, 2005.
DOI : 10.3201/eid0809.020238

S. Dewhurst, Human herpesvirus type 6 and human herpesvirus type 7 infections of the central nervous system, Herpes, vol.11, pp.105-111, 2004.

M. Yoshida, M. Yamada, T. Tsukazaki, S. Chatterjee, F. Lakeman et al., Comparison of antiviral compounds against human herpesvirus 6 and 7, Antiviral Research, vol.40, issue.1-2, pp.73-84, 1998.
DOI : 10.1016/S0166-3542(98)00049-7

D. Rapaport, D. Engelhard, G. Tagger, R. Or, and N. Frenkel, Antiviral prophylaxis may prevent human herpesvirus-6 reactivation in bone marrow transplant recipients, Transplant Infectious Disease, vol.28, issue.1, pp.10-16, 2002.
DOI : 10.1046/j.1365-2141.1999.01443.x

S. Tokimasa, J. Hara, Y. Osugi, H. Ohta, Y. Matsuda et al., Ganciclovir is effective for prophylaxis and treatment of human herpesvirus-6 in allogeneic stem cell transplantation, Bone Marrow Transplantation, vol.56, issue.7, pp.595-598, 2002.
DOI : 10.2165/00003495-199856010-00012

B. Mookerjee and G. Vogelsang, Human herpes virus-6 encephalitis after bone marrow transplantation: successful treatment with ganciclovir, Bone Marrow Transplantation, vol.20, issue.10, pp.905-990, 1997.
DOI : 10.1038/sj.bmt.1700988

D. Zerr, D. Gupta, M. Huang, R. Carter, and L. Corey, Effect of Antivirals on Human Herpesvirus 6 Replication in Hematopoietic Stem Cell Transplant Recipients, Clinical Infectious Diseases, vol.323, issue.25, pp.309-317, 2002.
DOI : 10.1056/NEJM199012203232502

P. Martin, N. Bleyzac, G. Souillet, C. Galambrun, Y. Bertrand et al., Relationship between CsA trough blood concentration and severity of acute graft-versus-host disease after paediatric stem cell transplantation from matched-sibling or unrelated donors, Bone Marrow Transplantation, vol.19, issue.Suppl 2, pp.777-784, 2003.
DOI : 10.1038/sj.bmt.1700745

K. Atkinson, C. Arthur, and K. Bradstock, one-hour infusions 18 mg /kg /d 3 two-hours infusions 24 mg /kg /d 3 two-hours infusions 16 mg /kg /d 3 two-hours infusions GCV therapy start GCV therapy stop 5 mg /kg /d GCV through (pl) 0.24 µg/ml GCV peak (pl) 5.07 µg/ml GCV through (pl) 0.7 µg/ml GCV through (pl) 1.1 µg/ml Infection regression Figure 1 Summary of GCV dosage schedule. Letter to the Editor References 1 Prophylactic ganciclovir is more effective in HLA-Identical family member marrow transplant recipients than in more heavily immune-suppressed HLA-identical unrelated donor marrow transplant recipients, D53 post BMT D57 D62 D67 D73 D84 10 mg

H. Einsele, H. Hebart, and C. Kauffmann-schneider, Risk factors for treatment failures in patients receiving PCR-based preemptive therapy for CMV infection, Bone Marrow Transplantation, vol.333, issue.7
DOI : 10.1056/NEJM199510193331603

S. Forman and J. Zaia, Treatment and prevention of cytomegalovirus pneumonia after bone marrow transplantation: where do we stand?, Blood, vol.83, pp.392-398, 1994.

M. Holberg-petersen, H. Rollag, and S. Beck, Direct growth suppression of myeloid bone marrow progenitor cells but not cord blood progenitors by human cytomegalovirus in vitro, Blood, vol.88, pp.2510-2516, 1996.

T. Mori, S. Okamoto, and R. Watanabe, Dose-adjusted preemptive therapy for cytomegalovirus disease based on real-time polymerase chain reaction after allogeneic hematopoietic stem cell transplantation, Bone Marrow Transplantation, vol.97, issue.9, pp.777-782, 2002.
DOI : 10.1182/blood.V97.5.1232

A. Tomonari, T. Iseki, and S. Takahashi, Ganciclovir-related neutropenia after preemptive therapy for cytomegalovirus infection: comparison between cord blood and bone marrow transplantation, Annals of Hematology, vol.83, issue.9, pp.573-577, 2004.
DOI : 10.1007/s00277-004-0887-2

J. Mcgavin and K. Goa, Ganciclovir, Drugs, vol.168, issue.7, pp.1153-1183, 2001.
DOI : 10.1093/infdis/168.2.332

G. Filler, D. Lampe, V. Bredow, and M. , Prophylactic oral ganciclovir after renal transplantation-dosing and pharmacokinetics, Pediatric Nephrology, vol.12, issue.1, pp.6-9, 1998.
DOI : 10.1007/s004670050391

C. Fletcher, R. Sawchuk, B. Chinnock, D. Miranda, P. Balfour et al., Human pharmacokinetics of the antiviral drug DHPG, Clinical Pharmacology and Therapeutics, vol.40, issue.3, pp.281-286, 1986.
DOI : 10.1038/clpt.1986.177

E. Greanya and M. Ensom, Therapeutic drug monitoring of ganciclovir in bone marrow transplants, Eur J Hosp Pharm, vol.11, pp.43-45, 2005.

J. Scott, N. Partovi, and M. Ensom, Ganciclovir in Solid Organ Transplant Recipients, Therapeutic Drug Monitoring, vol.26, issue.1, pp.68-77, 2004.
DOI : 10.1097/00007691-200402000-00014

D. Smee, R. Boehme, M. Chernow, B. Binko, and T. Matthews, Intracellular metabolism and enzymatic phosphorylation of 9-(1-3-dihydroxy-2-propoxymethyl)

B. Salzberger, R. Bowden, R. Hackman, C. Davis, and M. Boeckh, Neutropenia in allogeneic marrow transplant recipients receiving ganciclovir for prevention of cytomegalovirus disease: Risk factors and outcome, Blood, vol.90, pp.2502-2508, 1997.

J. Sommadossi and R. Carlisle, Toxicity of 3'-azido-3'-deoxythymidine and 9-(1,3-dihydroxy-2-propoxymethyl)guanine for normal human hematopoietic progenitor cells in vitro., Antimicrobial Agents and Chemotherapy, vol.31, issue.3, pp.452-454, 1987.
DOI : 10.1128/AAC.31.3.452

W. Heagy, C. Crumpacker, P. Lopez, and R. Finberg, Inhibition of immune functions by antiviral drugs., Journal of Clinical Investigation, vol.87, issue.6, pp.1916-1924, 1991.
DOI : 10.1172/JCI115217

J. Randolph-habecker, M. Iwata, and B. Torok-storb, Cytomegalovirus mediated myelosuppression, Journal of Clinical Virology, vol.25, pp.51-56, 2002.
DOI : 10.1016/S1386-6532(02)00092-6

S. Giebel, R. Maccario, and D. Lilleri, The immunosuppressive effect of human cytomegalovirus infection in recipients of allogeneic hematopoietic stem cell transplantation, Bone Marrow Transplantation, vol.29, issue.6, pp.503-509, 2005.
DOI : 10.1038/sj.bmt.1703332

B. Torok-storb, P. Simmons, D. Khaira, D. Stachel, and D. Myerson, Cytomegalovirus and marrow function, Annals of Hematology, vol.12, issue.S1, pp.128-131, 1992.
DOI : 10.1093/clinids/12.Supplement_7.S776

R. Dornsife and D. Averett, In vitro potency of inhibition by antiviral drugs of hematopoietic progenitor colony formation correlates with exposure at hemotoxic levels in human immunodeficiency virus positive humans, Antimicrob Agents Chemother, vol.40, pp.514-519, 1996.

R. Snoeck, L. Lagneaux, and A. Delforge, Inhibitory effects of potent inhibitors of human immunodeficiency virus and cytomegalovirus on the growth of human granulocyte-macrophage progenitor cells in vitro, European Journal of Clinical Microbiology & Infectious Diseases, vol.17, issue.Supplement 3, pp.615-619, 1990.
DOI : 10.1128/AAC.21.1.146

K. Biron, S. Stanat, and J. Sorrell, Metabolic activation of the nucleoside analog 9-[( 2-hydroxy-1-(hydroxymethyl)ethoxy]methyl)guanine in human diploid fibroblasts infected with human cytomegalovirus., Proceedings of the National Academy of Sciences, vol.82, issue.8, pp.2473-2477, 1985.
DOI : 10.1073/pnas.82.8.2473

V. Freitas, D. Smee, M. Chernow, R. Boehme, and T. Matthews, Activity of 9-(1,3-dihydroxy-2-propoxymethyl)guanine compared with that of acyclovir against human, monkey, and rodent cytomegaloviruses., Antimicrobial Agents and Chemotherapy, vol.28, issue.2, pp.240-245, 1985.
DOI : 10.1128/AAC.28.2.240

S. Clair, M. Lambe, C. Furman, and P. , Inhibition by ganciclovir of cell growth and DNA synthesis of cells biochemically transformed with herpesvirus genetic information., Antimicrobial Agents and Chemotherapy, vol.31, issue.6, pp.844-849, 1987.
DOI : 10.1128/AAC.31.6.844

S. Clair, M. Miller, W. Miller, R. Lambe, C. Furman et al., Inhibition of cellular alpha DNA polymerase and herpes simplex virus-induced DNA polymerases by the triphosphate of BW759U., Antimicrobial Agents and Chemotherapy, vol.25, issue.2, pp.191-194, 1984.
DOI : 10.1128/AAC.25.2.191

J. Arevalo, R. Garcia, and A. Mendoza, High-dose (5000-??g) Intravitreal Ganciclovir Combined with Highly Active Antiretroviral Therapy for Cytomegalovirus Retinitis in HIV-Infected Patients in Venezuela, European Journal of Ophthalmology, vol.346, issue.5, pp.610-618, 2005.
DOI : 10.1056/NEJMoa011759

J. Lalezari, D. Friedberg, and J. Bissett, High dose oral ganciclovir treatment for cytomegalovirus retinitis, Journal of Clinical Virology, vol.24, issue.1-2, pp.67-77, 2002.
DOI : 10.1016/S1386-6532(01)00229-3

G. Velez, C. Roy, S. Whitcup, C. Chan, and M. Robinson, High-dose intravitreal ganciclovir and foscarnet for cytomegalovirus retinitis, American Journal of Ophthalmology, vol.131, issue.3, pp.396-397, 2001.
DOI : 10.1016/S0002-9394(00)00785-6

S. Young, N. Morlet, and G. Besen, High-dose (2000-??g) intravitreous ganciclovir in the treatment of cytomegalovirus retinitis11The authors have no financial interest in the drugs or methods described in this article., Ophthalmology, vol.105, issue.8, pp.1404-1410, 1998.
DOI : 10.1016/S0161-6420(98)98020-4